NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023<
17 Nov 2023

Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023

aXess demonstrated exceptional patency rates and no infections to date
Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX<
16 Nov 2023

Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX

CALYX has been designed as a Phase 3 trial to confirm the disease modifying potential of leriglitazone

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update<
13 Nov 2023

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED
Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023<
11 Nov 2023

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of positive feedback loop linking obesity, leptin and aldosterone.
Publication in Nature Cell Biology deciphers the mechanism by which the MAF protein promotes breast cancer metastasis<
10 Nov 2023

Publication in Nature Cell Biology deciphers the mechanism by which the MAF protein promotes breast cancer metastasis

Results opens the possibility of an additional clinical utility of MAF Test®.
NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting<
10 Nov 2023

NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting

Study results identify NASH patients with Type 2 Diabetes as the key target population for Icosabutate therapy
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights<
09 Nov 2023

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial
Kynexis Launched to Advance Precision Therapeutics for Brain Diseases<
07 Nov 2023

Kynexis Launched to Advance Precision Therapeutics for Brain Diseases

Company co-founded by Forbion and Ysios Capital
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update<
07 Nov 2023

Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023.
Aura Biosciences Announces Proposed Public Offering of Common Stock<
06 Nov 2023

Aura Biosciences Announces Proposed Public Offering of Common Stock

Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15%

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.